(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are SAS AB, OCEANTEAM, and AKER HORIZONS.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| SAS AB (SASNO.OL) | 0.30 | 11.38% | 2023-10-03 12:43:05 |
| OCEANTEAM (OTS.OL) | 1.59 | 7.09% | 2023-10-03 12:41:58 |
| AKER HORIZONS (AKH.OL) | 4.96 | 5.8% | 2023-10-03 12:25:20 |
| VEON (VEON.AS) | 0.80 | 5.26% | 2023-10-03 12:05:12 |
| TREASURE (TRE.OL) | 22.00 | 4.76% | 2023-10-03 12:44:33 |
| REINET INVESTMENTS (REINA.AS) | 20.40 | 4.08% | 2023-10-03 12:04:23 |
| NAPATECH (NAPA.OL) | 11.20 | 3.7% | 2023-10-03 12:41:26 |
| DGB GROUP N.V. (DGB.AS) | 0.41 | 3.5% | 2023-10-03 12:01:56 |
| VISTIN PHARMA (VISTN.OL) | 24.00 | 3.45% | 2023-10-03 12:44:39 |
| ALTAMIR (LTA.PA) | 25.50 | 3.24% | 2023-10-03 12:46:08 |
The three biggest losers today are ATENOR, ADOCIA, and ONWARD MEDICAL.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| ATENOR (ATEB.BR) | 9.78 | -16.41% | 2023-10-03 12:05:48 |
| ADOCIA (ADOC.PA) | 7.68 | -13.42% | 2023-10-03 12:45:37 |
| ONWARD MEDICAL (ONWD.BR) | 3.55 | -10.35% | 2023-10-03 12:21:11 |
| UNIFIEDPOST GROUP (UPG.BR) | 2.17 | -9.79% | 2023-10-03 12:22:15 |
| MITHRA (MITRA.BR) | 1.15 | -9.43% | 2023-10-03 12:20:52 |
| AB SCIENCE (AB.PA) | 2.37 | -8.67% | 2023-10-03 12:45:11 |
| AKER CARBON CAPTUR (ACC.OL) | 9.80 | -8.5% | 2023-10-03 12:25:18 |
| BIOSENIC (BIOS.BR) | 0.10 | -8.09% | 2023-10-03 12:06:12 |
| PCI BIOTECH HOLD (PCIB.OL) | 1.38 | -7.26% | 2023-10-03 12:42:23 |
| ZALARIS (ZAL.OL) | 44.10 | -5.97% | 2023-10-03 12:45:07 |
Winners today
1. SAS AB (SASNO.OL)
11.38% Price Change
SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 135 aircraft, including 12 long-haul aircraft, 95 short-haul aircraft, and 28 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Oslo Børs Benchmark Index_GI ended the session with SAS AB jumping 11.38% to €0.30 on Tuesday, after three consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI dropped 1.42% to €1,263.05, following the last session’s downward trend on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, SAS AB has a trailing twelve months EPS of kr-0.7.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SAS AB’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for SAS AB is 38882300 which is 1216.6% above its average volume of 2953210.
Volatility
SAS AB’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.72%, a negative 1.43%, and a positive 1.84%.
SAS AB’s highest amplitude of average volatility was 5.21% (last week), 2.76% (last month), and 1.84% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
SAS AB’s EBITDA is 0.88.
More news about SAS AB.
2. OCEANTEAM (OTS.OL)
7.09% Price Change
Oceanteam ASA operates as a subsea and offshore services company in Europe. It provides equipment for offshore cable laying, umbilical installations, and on- and offshore storage and transport. The company also rents turntables, tensioners, reels, demountable turntable systems, and other cable handling and storage equipment, as well as offers cable and umbilical storage, and handling solutions. It serves renewable energy, and oil and gas industries. The company was formerly known as Oceanteam Shipping ASA and changed its name to Oceanteam ASA in December 2015. Oceanteam ASA was incorporated in 2005 and is headquartered in Bærum, Norway.
Oslo Børs Benchmark Index_GI ended the session with OCEANTEAM rising 7.09% to €1.59 on Tuesday while Oslo Børs Benchmark Index_GI fell 1.42% to €1,263.05.
Earnings Per Share
As for profitability, OCEANTEAM has a trailing twelve months EPS of kr-0.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.62%.
Moving Average
OCEANTEAM’s value is under its 50-day moving average of kr1.64 and above its 200-day moving average of kr1.59.
Yearly Top and Bottom Value
OCEANTEAM’s stock is valued at kr1.59 at 22:40 EST, way below its 52-week high of kr2.19 and way higher than its 52-week low of kr1.26.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 70k for the twelve trailing months.
Volume
Today’s last reported volume for OCEANTEAM is 24915 which is 18.7% above its average volume of 20989.
More news about OCEANTEAM.
3. AKER HORIZONS (AKH.OL)
5.8% Price Change
Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA is a subsidiary of Aker Capital AS.
Oslo Børs Benchmark Index_GI ended the session with AKER HORIZONS rising 5.8% to €4.96 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.42% to €1,263.05.
Earnings Per Share
As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-10.13.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.14%.
More news about AKER HORIZONS.
4. VEON (VEON.AS)
5.26% Price Change
VEON Ltd., together with its subsidiaries, provides mobile and fixed-line telecommunications services It offers voice, data, and other telecommunication services through a range of wireless, fixed, and broadband internet services. The company provides value-added services, including short messages, multimedia messages, caller number identification, call waiting, data transmission, mobile internet, downloadable content, mobile finance, machine-to-machine, and other services; national and international roaming services; wireless internet access; internet-TV services; digital and systems integration services; mobile financial services; and mobile bundles and call completion services. It offers value-added services for corporations, operators, and consumers, as well as sells equipment, infrastructure, and accessories. The company provides its services under the Beeline, Kyicvcstar, Jazz, Djezzy, and banglalink brands in Russia, Pakistan, Algeria, Uzbekistan, Ukraine, Bangladesh, Kazakhstan, Kyrgyzstan, and Georgia. The company was formerly known as VimpelCom Ltd. and changed its name to VEON Ltd. in March 2017. VEON Ltd. was founded in 1992 and is headquartered in Amsterdam, the Netherlands.
AEX-Index ended the session with VEON jumping 5.26% to €0.80 on Tuesday, after three sequential sessions in a row of gains. AEX-Index slid 0.62% to €719.67, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, VEON has a trailing twelve months EPS of €0.27.
PE Ratio
VEON has a trailing twelve months price to earnings ratio of 2.96. Meaning, the purchaser of the share is investing €2.96 for every euro of annual earnings.
More news about VEON.
5. TREASURE (TRE.OL)
4.76% Price Change
Treasure ASA, through its 11% interest in Hyundai Glovis Co. Ltd., provides transportation and logistics services in South Korea. The company was incorporated in 2016 and is based in Lysaker, Norway. Treasure ASA is a subsidiary of Wilh. Wilhelmsen Holding ASA.
Oslo Børs Benchmark Index_GI ended the session with TREASURE rising 4.76% to €22.00 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.42% to €1,263.05.
Earnings Per Share
As for profitability, TREASURE has a trailing twelve months EPS of kr3.34.
PE Ratio
TREASURE has a trailing twelve months price to earnings ratio of 6.59. Meaning, the purchaser of the share is investing kr6.59 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.46%.
More news about TREASURE.
6. REINET INVESTMENTS (REINA.AS)
4.08% Price Change
Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg City, Luxembourg.
AEX-Index ended the session with REINET INVESTMENTS rising 4.08% to €20.40 on Tuesday while AEX-Index fell 0.62% to €719.67.
Earnings Per Share
As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €-0.66.
More news about REINET INVESTMENTS.
7. NAPATECH (NAPA.OL)
3.7% Price Change
Napatech A/S offers reconfigurable computing solutions for the networking and cybersecurity applications worldwide. The company provides Link Capture Software that enables packet capture with nanosecond timestamping and replay with precise inter-frame gap control; Link Inline Software, which offers a processing architecture that offloads and accelerates flow aware application data planes; Link Virtualization Software that offloads and accelerates the Open vSwitch data plane to enhance CPU efficiency and network performance; and Link Programmable, which enables end users and OEMs to deploy FPGA computation solutions. It also offers solutions for telecom operators, cloud and data center service providers, and infrastructure and defense, as well as financial services, cyber security, network management, and virtualization. The company was incorporated in 2003 and is headquartered in Copenhagen, Denmark.
Oslo Børs Benchmark Index_GI ended the session with NAPATECH rising 3.7% to €11.20 on Tuesday while Oslo Børs Benchmark Index_GI fell 1.42% to €1,263.05.
Earnings Per Share
As for profitability, NAPATECH has a trailing twelve months EPS of kr-1.18.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.61%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 145.85M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NAPATECH’s stock is considered to be oversold (<=20).
More news about NAPATECH.
8. DGB GROUP N.V. (DGB.AS)
3.5% Price Change
DGB Group N.V. invests in, develops, and manages biodiversity and carbon offset, and nature-based projects for businesses and governments in the Netherlands and internationally. The company offers nature-based solutions comprising the management and use of nature for tackling social and environmental challenges; carbon offsetting projects for reducing carbon footprint of companies; and biodiversity protection and ecosystem services. It also provides ESG reporting and tree integration services. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 and is based in Haarlemmermeer, the Netherlands.
AEX-Index ended the session with DGB GROUP N.V. rising 3.5% to €0.41 on Tuesday while AEX-Index dropped 0.62% to €719.67.
Earnings Per Share
As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.11.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.92%.
More news about DGB GROUP N.V..
9. VISTIN PHARMA (VISTN.OL)
3.45% Price Change
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with VISTIN PHARMA jumping 3.45% to €24.00 on Tuesday while Oslo Børs Benchmark Index_GI fell 1.42% to €1,263.05.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.32.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 75. Meaning, the purchaser of the share is investing kr75 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
More news about VISTIN PHARMA.
10. ALTAMIR (LTA.PA)
3.24% Price Change
Altamir SCA, formerly known as Altamir Amboise, is a private equity investment arm of Amboise SAS, specializing in both direct and fund of fund investments, small and mid-cap companies. In direct investing, the firm specializes in middle market, buyout and growth capital investments. The firm prefers to invest in under-developed divisions of larger corporations. It prefers to invest in private equity funds specializing in growth capital and leverage buyouts investments from Europe, United States and Canada. The firm typically invests in the following sectors: healthcare, TMT, digital companies, consumer services, education services, retail and distribution. It also invests in retail and consumer, business and financial services. In healthcare, it seeks to focus on companies with strong growth potential in areas such as health services (hospitalization structures, home health care and medical analysis); medical devices; in niche pharmaceutical laboratories; and companies in related activities such as dermo-cosmetics, galenic development, and services and databases for health organizations. The firm seeks to invest in unlisted companies based in Europe, with a particular focus on Belgium, France, Luxembourg, Switzerland, Monaco, Italy, Netherlands, Germany and French-speaking Europe; United States and Canada and in larger emerging markets such as China, India and Brazil. In small and mid-cap companies firm prefers to invest in Continental Europe with a focus in France, Italy and Benelux, & larger size companies in Europe, North America and emerging countries like China, India and Brazil. In small and mid-cap size companies it prefers to invest with enterprise value between €50 million ($55.36 million) and €500 million ($553.6 million) and in larger size companies it prefers to invest with enterprise value between €500 million ($553.60 million) and €3000 million ($3321.62 million). It invests in funds that seek to have a majority stake in its investments or be a lead shareholder. It invests and disinvests with the private equity funds of Apax Partners France and Amboise Investissement under the same conditions and also invests directly in funds managed or advised by Apax Partners France and Apax Partners LLC. The firm seeks to exit its investments within five years. It makes balance sheet investments. Altamir SCA was founded in 1995 and is based in Paris, France.
CAC 40 ended the session with ALTAMIR rising 3.24% to €25.50 on Tuesday, after five sequential sessions in a row of losses. CAC 40 slid 1.01% to €6,997.05, following the last session’s downward trend on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, ALTAMIR has a trailing twelve months EPS of €-0.74.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2%.
Yearly Top and Bottom Value
ALTAMIR’s stock is valued at €25.50 at 22:40 EST, way below its 52-week high of €28.60 and way higher than its 52-week low of €22.44.
More news about ALTAMIR.
Losers Today
1. ATENOR (ATEB.BR)
-16.41% Price Change
Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.
BEL 20 ended the session with ATENOR dropping 16.41% to €9.78 on Tuesday while BEL 20 slid 1.36% to €3,461.77.
Earnings Per Share
As for profitability, ATENOR has a trailing twelve months EPS of €-9.18.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATENOR’s stock is considered to be overbought (>=80).
More news about ATENOR.
2. ADOCIA (ADOC.PA)
-13.42% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA falling 13.42% to €7.68 on Tuesday while CAC 40 fell 1.01% to €6,997.05.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-2.62.
Revenue Growth
Year-on-year quarterly revenue growth grew by 96.9%, now sitting on 17.36M for the twelve trailing months.
Volume
Today’s last reported volume for ADOCIA is 544913 which is 69.44% above its average volume of 321589.
More news about ADOCIA.
3. ONWARD MEDICAL (ONWD.BR)
-10.35% Price Change
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.
BEL 20 ended the session with ONWARD MEDICAL dropping 10.35% to €3.55 on Tuesday while BEL 20 fell 1.36% to €3,461.77.
Earnings Per Share
As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.18.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.93%.
Volatility
ONWARD MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.84%, a negative 0.70%, and a positive 2.59%.
ONWARD MEDICAL’s highest amplitude of average volatility was 10.30% (last week), 5.38% (last month), and 2.59% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 2.11M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
ONWARD MEDICAL’s stock is valued at €3.55 at 22:40 EST, way under its 52-week high of €6.99 and way above its 52-week low of €3.15.
More news about ONWARD MEDICAL.
4. UNIFIEDPOST GROUP (UPG.BR)
-9.79% Price Change
UnifiedPost Group SA, a fintech company, operates and develops a cloud-based platform for administrative and financial services in Belgium and internationally. Its platform allows connections between its customers, suppliers, customers, and other parties in the financial supply chain. The company offers a technology portfolio for document processing, identity management, payment services, and added value financial services, as well as engages in post and parcel optimization activities. It serves corporate and government customers; small and medium-sized enterprises; and agricultural, accounting, interim, and construction sectors. UnifiedPost Group SA was founded in 2001 and is headquartered in La Hulpe, Belgium.
BEL 20 ended the session with UNIFIEDPOST GROUP dropping 9.79% to €2.17 on Tuesday while BEL 20 slid 1.36% to €3,461.77.
Earnings Per Share
As for profitability, UNIFIEDPOST GROUP has a trailing twelve months EPS of €-1.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.78%.
Yearly Top and Bottom Value
UNIFIEDPOST GROUP’s stock is valued at €2.17 at 22:40 EST, way under its 52-week low of €2.55.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UNIFIEDPOST GROUP’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.6%, now sitting on 192.46M for the twelve trailing months.
More news about UNIFIEDPOST GROUP.
5. MITHRA (MITRA.BR)
-9.43% Price Change
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
BEL 20 ended the session with MITHRA dropping 9.43% to €1.15 on Tuesday, after three sequential sessions in a row of losses. BEL 20 fell 1.36% to €3,461.77, following the last session’s downward trend on what was an all-around down trend trading session today.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-1.09.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -575.59%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MITHRA’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for MITHRA is 598263 which is 83.39% above its average volume of 326211.
Revenue Growth
Year-on-year quarterly revenue growth declined by 38.1%, now sitting on 62.67M for the twelve trailing months.
Moving Average
MITHRA’s worth is way below its 50-day moving average of €2.15 and way under its 200-day moving average of €2.62.
More news about MITHRA.
6. AB SCIENCE (AB.PA)
-8.67% Price Change
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
CAC 40 ended the session with AB SCIENCE sliding 8.67% to €2.37 on Tuesday while CAC 40 slid 1.01% to €6,997.05.
Earnings Per Share
As for profitability, AB SCIENCE has a trailing twelve months EPS of €-0.32.
Moving Average
AB SCIENCE’s value is way below its 50-day moving average of €3.77 and way below its 200-day moving average of €5.72.
More news about AB SCIENCE.
7. AKER CARBON CAPTUR (ACC.OL)
-8.5% Price Change
Aker Carbon Capture ASA provides products, technology, and solutions within the field of carbon capture technologies, utilization, and storage in Norway and internationally. The company's carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. It offers carbon capture plants under the Just Catch and Big Catch brands. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Carbon Capture ASA is a subsidiary of Aker Horizons Holding AS.
Oslo Børs Benchmark Index_GI ended the session with AKER CARBON CAPTUR dropping 8.5% to €9.80 on Tuesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI fell 1.42% to €1,263.05, following the last session’s downward trend on what was an all-around down trend exchanging session today.
Earnings Per Share
As for profitability, AKER CARBON CAPTUR has a trailing twelve months EPS of kr-0.34.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.58%.
Sales Growth
AKER CARBON CAPTUR’s sales growth is 90.1% for the current quarter and 86.6% for the next.
Volume
Today’s last reported volume for AKER CARBON CAPTUR is 1426040 which is 204.42% above its average volume of 468432.
Earnings Before Interest, Taxes, Depreciation, and Amortization
AKER CARBON CAPTUR’s EBITDA is 6.16.
Yearly Top and Bottom Value
AKER CARBON CAPTUR’s stock is valued at kr9.80 at 22:40 EST, way under its 52-week high of kr23.21 and higher than its 52-week low of kr9.26.
More news about AKER CARBON CAPTUR.
8. BIOSENIC (BIOS.BR)
-8.09% Price Change
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with BIOSENIC falling 8.09% to €0.10 on Tuesday while BEL 20 dropped 1.36% to €3,461.77.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €7.24.
PE Ratio
BIOSENIC has a trailing twelve months price to earnings ratio of 0.01. Meaning, the purchaser of the share is investing €0.01 for every euro of annual earnings.
More news about BIOSENIC.
9. PCI BIOTECH HOLD (PCIB.OL)
-7.26% Price Change
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD dropping 7.26% to €1.38 on Tuesday while Oslo Børs Benchmark Index_GI dropped 1.42% to €1,263.05.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.
More news about PCI BIOTECH HOLD.
10. ZALARIS (ZAL.OL)
-5.97% Price Change
Zalaris ASA provides full-service outsourced personnel and payroll services. The company operates in two segments, Managed Services and Professional Services. It offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services, such as talent management, digital personnel archive, HR analytics, mobile solutions, etc. The company also engages in the implementation of SAP HCM, and Payroll and SuccessFactors, as well as provides consulting services. It serves bank, insurance, finance, health and life science, infrastructure and transportation, IT, telecom, offshore and energy, product, retail, and service industries, as well as public services and other institutions. The company has operations in Norway, Sweden, Denmark, Finland, Germany, Latvia, the United Kingdom, Poland, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was incorporated in 2000 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with ZALARIS dropping 5.97% to €44.10 on Tuesday while Oslo Børs Benchmark Index_GI slid 1.42% to €1,263.05.
Earnings Per Share
As for profitability, ZALARIS has a trailing twelve months EPS of kr-2.14.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.01%.
More news about ZALARIS.
Stay up to date with our winners and losers daily report
